VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
USPHU.S. Physical Therapy, Inc.
$68.78$1.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksUSPHCash Flow

U.S. Physical Therapy, Inc. (USPH) Cash Flow Statement

30Y historyFree accessUpdated daily

Liquidity is tightening as cash reserves fell to $28.4 million in 2026Q1 from $152.8 million in 2023Q4, reflecting the heavy capital deployment required for ongoing acquisitions.

USPH Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations83.74M75.06M74.94M81.98M58.54M76.41M100M62.45M73M56.53M51.05M41.24M45.19M44.8M39.25M32.66M30.52M30.94M30.17M19.05M18.47M18.25M17.88M17.53M19.52M15.17M8.86M5.05M5M3.8M4.7M
Operating CF Margin %-9.61%11.16%13.55%10.58%15.43%23.64%12.96%16.08%13.65%14.32%12.45%14.81%16.96%15.57%13.78%14.45%15.36%16.08%12.56%13.66%13.81%15.12%16.61%20.61%18.74%14.02%10.11%11.36%9.79%14.6%
Operating CF Growth %223.79%0.16%-8.59%40.04%-23.39%-23.59%60.13%-14.46%29.15%10.73%23.78%-8.74%0.89%14.13%20.19%6.99%-1.37%2.56%58.41%3.11%1.21%2.06%2.01%-10.2%28.68%71.22%75.47%1%31.58%-19.15%95.83%
Net Income10.55M58.01M45.6M37.22M43.41M57.92M52.49M57.26M48.84M27.72M26.27M31.69M30.42M21M26.22M29.78M24.7M19.97M10M8.74M6.3M8.79M6.68M7.33M8.49M7.07M3.73M2.39M1.6M2.4M1.6M
Depreciation & Amortization22.52M22.39M18.68M15.7M14.74M11.59M10.53M10.1M9.76M9.71M8.78M7.95M6.74M5.56M5.29M5.45M5.67M5.9M5.97M4.99M4.49M4.31M4.32M3.59M2.96M2.57M2.33M2.09M2.1M1.9M1.7M
Stock-Based Compensation6.5M8.27M7.82M7.24M7.26M7.87M7.92M6.99M5.94M5.03M4.96M4.49M3.36M2.74M2.1M2.03M1.29M1.57M1.57M1.28M1.04M0000000000
Deferred Taxes9.45M11.41M5.37M4.49M4.31M5.69M-258K4.65M4.81M-4.55M2.98M7M6.28M2.37M3.74M3.83M452K714K1.92M313K-373K44K146K474K-319K-351K00300K00
Other Non-Cash Items24.46M2.18M9.88M22.27M10.24M5.12M5.67M-560K2.92M4.29M4.19M3.49M3.33M11.02M6.37M-1.25M2.16M2.93M9.93M7.84M8.16M7.06M7.79M8.01M10.83M10.25M5.35M3.75M-100K2.8M2.1M
Working Capital Changes-18.33M-27.19M-12.4M-4.93M-21.43M-11.78M23.64M-15.98M732K14.32M3.87M-13.38M-4.94M2.1M-4.47M-7.19M-3.75M-148K772K-4.11M-1.15M-1.95M-1.05M-1.87M-2.43M-4.36M-2.56M-3.19M-2.1M-3.3M-700K
Change in Receivables-10.98M-9.06M-11.89M-6M-10.28M-10.96M2.56M-6.38M-3.43M-3.45M-3.27M-5.52M-5.39M-5.39M-1.66M-6.14M-4.47M-303K-1.57M-3.54M-3.43M-3.22M000000000
Change in Inventory00000004.21M-742K-794K-1.45M-2.33M-2.15M1.8M-1.15M0-24.04M-19.97M252K-87K-73K-29.5M000000000
Change in Payables-2.57M-7.8M015K-7.75M00-4.21M4.88M6.98M2.99M-7.01M1.87M4.83M-340K1.19M-292K1.87M1.87M-655K1.62M1.04M000000000
Cash from Investing-70.08M-36.71M-149.45M-45.02M-81.27M-124.14M-51.2M-37.99M-23.91M-43.58M-32.49M-32.24M-22.88M-52.45M-14.1M-31.61M-21.63M-7.33M-24.88M-23.54M-8.85M-12.18M-4.96M-5.03M-6.63M-3.38M-2.8M-2.1M-2.5M-2.1M-2M
Capital Expenditures-16.86M-14.07M-9.19M-9.29M-8.25M-8.2M-7.64M-10.19M-7.19M-7.09M-8.26M-6.26M-5.17M-4.64M-4.23M-3.22M-3.67M-3.88M-4.3M-4.03M-4.66M-10.85M-4.97M-5.13M-5.57M-3.34M-2.83M-2.1M-2.4M-1.8M-2M
CapEx % of Revenue2.43%1.8%1.37%1.54%1.49%1.66%1.81%2.11%1.58%1.71%2.32%1.89%1.69%1.76%1.68%1.36%1.74%1.92%2.29%2.66%3.44%8.21%4.2%4.86%5.87%4.13%4.47%4.2%5.45%4.64%6.21%
Acquisitions-43.34M0-142.04M-36.87M-74.28M-116.09M-43.56M-27.87M-16.37M-36.56M-24.29M-26.05M-17.76M-48.5M-10.17M-9.45M-17.28M-1.18M-20.68M-20.02M-5.21M-1.51M000000000
Investments-------------------------------
Other Investing-9.88M-22.64M1.77M1.15M1.26M152K064K-349K81K61K71K5.54M2.33M303K-18.93M-17.96M57K108K21K-1.14M178K11K105K-1.07M-32K25K1K-100K-300K0
Cash from Financing-24.4M-44.14M-36.95M84.27M25.76M43.38M-39.42M-24.27M-47.66M-11.06M-14.29M-7.5M-20.94M8.88M-23.46M-245K-6.14M-27.3M-3.16M1.51M-11.03M-11.62M-9.19M-3.29M-13.4M-5.75M-8.02M-5.25M-1.7M-1.1M-500K
Debt Issued (Net)36.83M8.06M4.3M-39.15M64.19M93.1M-31.04M6.57M-20.04M6.77M1.2M8.62M-6.33M22.14M-6.53M17.75M4.09M-12.38M3.51M6.41M-245K-153K-52K-38K-701K-1.54M862K-32K-100K-100K200K
Equity Issued (Net)-5.57M-5.57M0163.65M00000000000-4.66M-1.4M-5.59M495K568K-5.4M-6.2M-3.81M1.44M-7.51M336K-5.88M-3.28M000
Dividends Paid-27.36M-27.36M-26.54M-24.13M-21.32M-18.77M-4.11M-14.55M-11.66M-10.07M-8.51M-7.45M-5.87M-4.84M-9.02M-3.79M-9.58M-9.44M0000000000000
Share Repurchases-5.57M-5.57M00000502K0000000-4.66M-1.4M-5.59M00-5.52M-8M-5.58M-20K-10.51M-1.94M-6.28M-3.41M000
Other Financing-28.3M-19.27M-14.71M-16.1M-17.11M-30.96M-4.28M-16.29M-15.95M-7.77M-6.98M-4.94M-8.74M-8.42M-7.91M-9.55M-8.82M101K128K-5.47M-5.38M-5.27M-5.33M-4.7M-5.19M-4.54M-3M-1.94M-1.6M-1M-700K
Net Change in Cash-10.74M-5.79M-111.46M121.23M3.03M-4.35M9.37M180K1.44M1.89M4.27M1.51M1.37M1.23M1.69M804K2.75M-3.68M2.14M-2.98M-1.4M-5.55M3.73M9.21M-511K6.05M-1.96M-2.3M800K600K2.2M
Free Cash Flow66.87M60.99M65.75M72.68M50.29M68.2M92.36M52.26M65.81M49.43M42.79M34.98M40.03M40.16M35.02M29.43M26.85M27.07M25.87M15.01M13.82M7.4M12.91M12.4M13.96M11.83M6.03M2.95M2.6M2M2.7M
FCF Margin %9.62%7.81%9.79%12.02%9.09%13.78%21.84%10.84%14.5%11.94%12%10.56%13.12%15.21%13.89%12.42%12.71%13.44%13.79%9.9%10.22%5.6%10.92%11.74%14.73%14.61%9.54%5.91%5.91%5.15%8.39%
FCF Growth %19.23%-7.25%-9.53%44.53%-26.27%-26.15%76.73%-20.59%33.14%15.52%22.33%-12.61%-0.33%14.69%18.97%9.63%-0.81%4.62%72.34%8.66%86.62%-42.67%4.15%-11.18%18.02%96.02%104.33%13.58%30%-25.93%200%
FCF per Share4.414.024.365.123.875.297.204.105.203.933.422.823.283.322.942.462.262.292.151.281.180.611.041.031.100.920.560.300.240.180.26
FCF Conversion (FCF/Net Income)6.34x4.98x2.83x5.59x2.07x2.75x3.27x2.22x7.23x2.54x2.48x1.85x2.29x3.52x2.19x1.56x1.95x2.63x3.02x2.14x2.93x2.08x2.68x2.39x2.30x2.15x2.37x2.11x3.13x1.58x2.94x
Interest Paid5.1M07.21M8.65M5.69M1.35M1.2M1.89M2.36M2.11M784K884K1.1M352K639K325K179K324K484K000000000000
Taxes Paid4.45M04.83M4.93M7.62M12.21M7.68M9.86M9.18M8.54M10.58M7.78M9.25M4.11M6.36M9.04M7.8M8.45M4.4M000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Labor cost inflation pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Volatility

As reported in recent financial statements, USPH exhibits extreme variance in its OCF/NI ratio, which swung from a negative 3.39 in 2023Q4 to a positive 4.24 in 2024Q2, indicating that net income is a poor proxy for the company's actual cash-generating capability in any given quarter.

The significant divergence between net income and operating cash flow suggests that non-cash items and accounting adjustments related to the partnership model frequently distort bottom-line performance. Investors should monitor whether these fluctuations represent genuine operational volatility or merely the timing of cash distributions to minority partners.

Free Cash Flow Margin Instability

Based on quarterly data, USPH's free cash flow margins have demonstrated high sensitivity to operational cycles, oscillating from a negative 4.8% in 2025Q1 to a peak of 19.3% in 2025Q2, reflecting a lack of consistent cash flow generation relative to the company's revenue base.

This erratic trajectory implies that the company's ability to retain cash after capital expenditures is highly dependent on short-term working capital management rather than structural margin expansion. The inability to maintain a stable FCF margin warrants further investigation into the predictability of the company's core clinical operations.

Working Capital Swings Impede Liquidity

According to recent SEC filings, USPH experienced a substantial working capital outflow of $28.3 million in 2025Q1, which directly contributed to a negative operating cash flow for that period, highlighting the company's vulnerability to timing differences in healthcare billing and collections cycles.

The recurring, large-scale swings in working capital suggest that the company's cash position is frequently impacted by the complexities of its reimbursement environment. This volatility may indicate that the firm's cash conversion cycle is susceptible to external delays, potentially complicating short-term liquidity planning.

Acquisition-Heavy Capital Allocation Strategy

As evidenced by the $93.4 million net acquisition spend in 2024Q4, USPH prioritizes aggressive inorganic growth, which frequently consumes the majority of available free cash flow and necessitates a disciplined approach to balancing expansion with the maintenance of its partnership-based clinic model.

The reliance on acquisitions to drive growth appears to be a double-edged sword, as it requires constant capital deployment that can leave the company cash-constrained during periods of operational underperformance. Investors should monitor whether these acquisitions provide sufficient incremental returns to justify the ongoing pressure on free cash flow.

USPH — Frequently Asked Questions

Quick answers to the most common questions about buying USPH stock.

How much cash does U.S. Physical Therapy, Inc. (USPH) generate from operations?

U.S. Physical Therapy, Inc. (USPH) generated $75.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is U.S. Physical Therapy, Inc.'s free cash flow?

U.S. Physical Therapy, Inc. (USPH) generated $61.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is U.S. Physical Therapy, Inc.'s capital expenditure (CapEx)?

U.S. Physical Therapy, Inc. (USPH) spent $14.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does U.S. Physical Therapy, Inc. distribute cash to shareholders?

In 2025, U.S. Physical Therapy, Inc. (USPH) returned $27.4M to shareholders via cash dividends and spent $5.6M on share repurchases. This shows the company's commitment to returning capital to its equity investors.